AAAAAA

   
Results: 1-11 |
Results: 11
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
Authors: Champlin, R Khouri, I Anderlini, P Gajewski, J Kornblau, S Molldrem, J Shimoni, A Ueno, N Giralt, S
Citation: R. Champlin et al., Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation, BONE MAR TR, 27, 2001, pp. S13-S22
Diagnostic utility of flow cytometric immunophenotyping in myelodysplasticsyndrome
Authors: Stetler-Stevenson, M Arthur, DC Jabbour, N Xie, XY Molldrem, J Barrett, AJ Venzon, D Rick, ME
Citation: M. Stetler-stevenson et al., Diagnostic utility of flow cytometric immunophenotyping in myelodysplasticsyndrome, BLOOD, 98(4), 2001, pp. 979-987
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer
Authors: Donato, ML Gershenson, D Ippoliti, C Wharton, JT Bast, RC Aleman, A Anderlini, P Gajewski, JG Giralt, S Molldrem, J Ueno, N Lauppe, J Korbling, M Boyer, J Bodurka-Bevers, D Bevers, M Burke, T Freedman, R Levenback, C Wolf, J Champlin, RE
Citation: Ml. Donato et al., High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer, BONE MAR TR, 25(11), 2000, pp. 1137-1140
Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?
Authors: Barrett, J Saunthararajah, Y Molldrem, J
Citation: J. Barrett et al., Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?, SEM HEMATOL, 37(1), 2000, pp. 15-29
Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
Authors: Champlin, R Khouri, I Shimoni, A Gajewski, J Kornblau, S Molldrem, J Ueno, N Giralt, S Anderlini, P
Citation: R. Champlin et al., Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy, BR J HAEM, 111(1), 2000, pp. 18-29
Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia
Authors: Clave, E Molldrem, J Hensel, N Raptis, A Barrett, AJ
Citation: E. Clave et al., Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia, J IMMUNOTH, 22(1), 1999, pp. 1-6
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Authors: Przepiorka, D van Besien, K Khouri, I Hagemeister, F Samuels, B Folloder, J Ueno, NT Molldrem, J Mehra, R Korbling, M Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I Andersson, B Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma, ANN ONCOL, 10(5), 1999, pp. 527-532
Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy
Authors: Champlin, R Khouri, I Kornblau, S Marini, F Anderlini, P Ueno, NT Molldrem, J Giralt, S
Citation: R. Champlin et al., Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy, HEMAT ONCOL, 13(5), 1999, pp. 1041
High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients
Authors: Raptis, A Mavroudis, D Suffredini, AF Molldrem, J Van Rhee, F Childs, R Phang, S Barrett, AJ
Citation: A. Raptis et al., High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients, BONE MAR TR, 24(8), 1999, pp. 879-883
A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method
Authors: Hensel, N Agarwala, V Jiang, YZ Mavroudis, D Molldrem, J Barrett, AJ
Citation: N. Hensel et al., A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method, BONE MAR TR, 23(1), 1999, pp. 71-78
Risultati: 1-11 |